With cases of avian influenza A (H5N1) continuing to rise among cattle and humans in the US, scientists and government health officials are preparing for the potential of the virus adapting to enable human-to-human transmission. While there is no evidence yet that H5N1 could spread between humans, pandemic preparedness is essential, and mRNA vaccines offer great potential to mitigate a future pandemic, says GlobalData, a leading data and analytics company.
Leia Mais »International News
Abu Dhabi to host inaugural Pharma Logistics Winter University
The inaugural Pharma Logistics Winter University, co-founded by the Department of Health – Abu Dhabi, Etihad Cargo, Pharma.Aero, the University of Antwerp, and Khalifa University of Science and Technology, offers an immersive five-day programme in Abu Dhabi, bridging academic learning with practical application to cultivate future global leaders in pharmaceutical logistics.
Leia Mais »Heart failure market to grow at 9.6% CAGR in 7MM during 2022-32, forecasts GlobalData
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a 9.6% compound annual growth rate (CAGR) from $13.5 billion in 2022 to $33.7 billion in 2032 across the seven major markets (7MM*), forecasts GlobalData, a leading data and analytics company.
Leia Mais »AbbVie’s tavapadon holds potential to become prominent treatment in dopamine agonist market, says GlobalData
AbbVie recently announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease (PD). Tavapadon, the first and only D1/D5 partial agonist in the dopamine agonist class, is under investigation as a once-daily treatment for PD. The trial met both its primary and secondary endpoints, suggesting that tavapadon has the potential to become a prominent treatment within the dopamine agonist market, says GlobalData, a leading data and analytics company.
Leia Mais »Unither Pharmaceuticals launches first commercial batches of Preservative-Free Multidose Ophthalmic products
Coutances, France – [December 12, 2024] – Unither Pharmaceuticals, a global leader in sterile liquid pharmaceutical formulations, has successfully launched the first commercial batches of Preservative-Free Multidose (PFMD) ophthalmic products at its Laboratoire Unither Coutances site in Normandy, France.
Leia Mais »Carmot acquisition propels Roche to forefront of obesity drug leadership
Carmot acquisition propels Roche to forefront of obesity drug leadership, finds GlobalData
In a significant move in December 2023, Roche completed the acquisition of the US-based company Carmot Therapeutics in a deal worth $2.9 billion. This strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. This acquisition positions Roche on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others, according to GlobalData, a leading data and analytics company.
GlobalData’s Technology Foresights model recognizes GLP-1 analogues as a high-impact innovation, with accelerating patent trends and other markers indicating their near-term impact. Notably, leaders in this space, like Novo Nordisk and Eli Lilly, have experienced significant success, with share prices surging over 20% in 2023 year on year due to the sales of their respective GLP-1 agonist brands, Wegovy and Mounjaro.
The Technology Foresights model also identifies over 70 companies, including early-stage ventures, actively developing innovative products utilizing GLP-1 analogues. The model further suggests that these molecules, primarily targeting obesity and type 2 diabetes, are also being explored for applications in neurological disorders and NASH type Hepatitis.
Sourabh Nyalkalkar, Practice Head of Innovation Products at GlobalData comments: “As a major player in the pharmaceutical industry, Roche has traditionally focused its research and development (R&D) efforts on cancer research, diagnostics, and gene therapies, as evidenced by the 120+ innovation areas tracked for Roche on the Technology Foresights model. However, innovations in lifestyle disorders, such as GLP-1 analogues, were not a key focus until this recent acquisition.”

On the other hand, Carmot Therapeutics, a privately held company, centred its innovation portfolio almost entirely on GLP-1 agonists. Two out of its four molecules have received positive responses in Phase I clinical trials, positioning Carmot among the leaders in the field of GLP-1 analogue innovation, as identified by GlobalData’s proprietary framework.
Sourabh concludes: “Roche’s well-timed move aligns with the resounding success of GLP-1 agonists like Ozempic, Wegovy, and Mounjaro. The shift in Roche’s position is evident on the innovation leadership map. This move also signals a potential trend, suggesting that other major pharmaceutical players with a strong market presence may be actively seeking targets with robust innovation portfolios in GLP-1 analogues. The Technology Foresights model emerges as a valuable tool for evaluating potential targets in this evolving landscape.”
Clasado Biosciences collaborates with leading scientists to advance prebiotics in medical nutrition field
Clasado Biosciences (‘Clasado’), developer of the proprietary prebiotic ingredient Bimuno GOS, is collaborating with esteemed scientists through a newly established scientific advisory board to further develop the future role of prebiotics within medical nutrition.
This strategic initiative highlights Clasado’s commitment to driving scientific advancements in the health and nutrition industry through microbiome modulation. Notably, this represents a step forward in the exploration and utilisation of prebiotics as part of dietary health interventions.
The collaboration consists of Clasado members Per Rehné (CEO), Dr Frederic Narbel (VP of Sales B2B) and Dr Lucien Harthoorn (R&D Director), and renowned scientific advisors:
- Prof Georg Holländer: Professor and Head of the Department of Paediatrics at the University of Oxford (UK), and Director of the Botnar Research Centre for Child Health (Basel, Switzerland). He is an expert in immunology with a keen interest in thymus and T cell biology and has authored over 100 publications in peer-reviewed journals.
- Prof Matthias Kloor: Deputy Medical Director at the Department of Applied Tumor Biology of the Institute of Pathology at Heidelberg University Hospital (DE), and author of more than 190 publications in peer-reviewed scientific journals. He has also received several scientific honours.
- Prof Huub Savelkoul: After being Professor in Cell Biology and Immunology from 2000 to 2022 at Wageningen University and Research (NL) he retired in 2023, and has published almost 400 peer-reviewed research papers. He has received several awards for his research and contribution to education.
Clasado is proud to be working with these experts to sharpen the scientific agenda and share valuable insights and experiences to propel the future of prebiotic development and use in medical nutrition and beyond.
A driving force in the biotics field, Clasado Biosciences has long been dedicated to advancing prebiotic research and innovation. With the insight of the scientific advisory board members, the company aims to uncover new possibilities for the application of prebiotics in critical health areas.
Dr Lucien Harthoorn, R&D Director at Clasado Biosciences, expressed the significance of the collaboration, stating: “The future of prebiotics, specifically galactooligosaccharides and potential novel oligosaccharides holds immense promise in the medical nutrition field – and we are working on uncovering the potential. Clasado’s strategic involvement in this area showcases our commitment to driving prebiotic capabilities forward, and we are honoured to work alongside such esteemed scientific advisors to achieve our shared goals.”
The scientific advisory board follows a submission involving Clasado, which enabled galactooligosaccharides (GOS) to be permitted by the European Commission for use in foods for special medical purposes (FSMPs), further driving the future potential of prebiotics in health and medical applications.
Per Rehné adds: “As we look to the future of medical nutrition, gut microbiome modulation holds great potential and could play a key role in improving human health. Driven by rising global awareness, eyes are on the capabilities of prebiotics, which makes initiatives such as the new scientific advisory board all the more important. For us, this represents an opportunity to better understand where prebiotics can fit into healthcare strategies. Through the power of science and collaboration, we’re aiming to expand the event horizon of the prebiotic category and how it could change areas of application.
“Through our continued research and discussion, we are painting a clearer picture of where prebiotics can support in the day to day management of health, such as gastrointestinal, immune and cognitive health, and we’re excited to be exploring the synergies beyond.”
For further information on Clasado Biosciences and the scientific excellence behind Bimuno GOS, please visit https://clasado.com
Amgen olpasiran may fill critical treatment gap in lowering Lp(a), opines GlobalData
Amgen’s olpasiran, a small interfering RNA (siRNA), is making strides in reducing Lp(a) levels significantly in patients with cardiovascular disease. This is noteworthy as elevated Lp(a) is considered a potent risk factor for heart disease and stroke. It also underscores olpasiran’s potential to address a vital treatment gap, representing a pivotal advancement in the realm of dyslipidemia, according to GlobalData, a leading data and analytics company.
The latest data from the final analysis of the Phase II OCEAN(a)-DOSE study showed that olpasiran reduced Lp(a) levels in patients by 95%. This study, which resulted from the off-treatment extension period, showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a) for nearly a year after their last dose.
Lp(a) is an atherogenic particle and an independent predictor of CV risk. Elevated levels of Lp(a) in the blood are considered a risk factor for CVD, including heart attack and stroke, as it promotes the formation of blood clots and plaque buildup in the arteries. There are a few strategies that have been shown to lower Lp(a) levels, including niacin, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, antisense oligonucleotides, and lifestyle modifications. GlobalData forecasts olpasiran sales to reach $1.05 billion in 2029.
Dr Shireen Mohammad, Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments:“At present, there are no specific therapies available in the market that target Lp(a) directly. The standard treatments for dyslipidemia, such as statins and other cholesterol-lowering drugs, are not effective in reducing Lp(a) levels. Therefore, there is a high level of unmet need for therapies targeting other lipid particles, particularly the Lp(a) particle.
“Olpasiran is a promising drug treatment for dyslipidemia as it works by preventing the assembly of Lp(a) and therefore the translation of the apo(a) protein, hence reducing Lp(a) in the circulation. Amgen is currently enrolling patients for a Phase III study.”
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
Data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines
Leia Mais »Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
London, UK, 28th June 2023 / Sciad Newswire / Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
Busy with networking and collaboration, the event focused on the most important themes for the future of the pharma industry, from manufacturing to drug delivery and sustainability to socioeconomic challenges. A particular highlight was the event’s Gala reception, where visitors enjoyed an awe-inspiring talk by Nicolas Hamilton, British Touring Car Championship Driver, who was given a standing ovation.
Industry change
With attendees from Google, McKinsey, Merck, GSK, Roche, and Johnson & Johnson, speakers highlighted the need to develop systems that account for future needs and create platforms that can be scaled through multiple networks simultaneously. Optimisation and manufacturing speed were key themes, as well as utilising data and AI to improve supply chains.
Elena Bayrak, Pipeline Strategy and Operations at Novartis, appreciated the sector-wide approach to tackling pressing topics:
“I really enjoyed how Connect in Pharma is bringing the pharma industry together with new technologies within packaging, drug delivery systems and such critical topics like diversity and sustainability.”
The ‘Women in Pharma’ panel tackled difficult topics such as inappropriate behaviour in the workplace, emphasising the need for diversity and equality, both for wellbeing and business success.
Global partnerships and data sharing
Over the two-day event, speakers from around the world discussed common issues. Collaboration on a global scale is required to make equitable changes that give the industry longevity. Questions from the audience focused on equity relating to low- and middle-income countries, asking the panel what is needed to facilitate effective sharing of technologies and innovation. Sharing innovation was also raised in the context of IP, calling for open data and increased access to inventions and advances worldwide.
AI and biotechnology
From biotech to connected devices, visitors at Connect in Pharma learned how technologies can empower doctors and healthcare professionals to be more efficient while keeping patients at the heart of healthcare. Futuristic concepts such as harnessing AI in the body, the bio-revolution, the miniverse and the metaverse were raised as important ideas. Promoting healthy lifestyles and wellness that allow people to better manage their health was an important theme in reducing stress on healthcare services.
Berhard Müllinger, Chief Operating Officer at REYSCA, appreciated the range of opinions and opportunities for connection:
“There was a broad selection of speakers. The panels produced lovely discussions and were open to lots of new opinions. There were lots of opportunities to meet new people. Connect in Pharma is a perfect conference for finding suppliers in lots of different industries.”
Exhibitors
Exhibitors representing a wide range of companies — including BD Medical, Gerresheimer, and Mettler-Toledo — highlighted innovative products and services designed to advance all areas of the pharma supply chain. With primary packaging solutions, medical device innovations, drug delivery system products, and numerous contract services, software platforms, and association groups on show, the exhibition area had a wide appeal to the pharma community.
Renan Joel, Divisional Managing Director for Packaging at Easyfairs, concluded: “We are thrilled with the success of this year’s event and the feedback we have received. With more than 70% of existing exhibitors pre-booking for next year, we’re excited about the trajectory of the event. This second edition of Connect in Pharma was an enormous success and represents the growing appetite for solutions in pharma, drug delivery and manufacturing, and we’re grateful for the support of the Directorate General for Economic Development, Research and Innovation (DG EDRI). We look forward to welcoming more of you to the event in June 2024.”